Search Results for “EC” – Page 151 – media

Novartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx® (secukinumab), the first interleukin-17A (IL-17A) antagonist approved to treat moderate to severe plaque psoriasis.1 The updated label includes Cosentyx data in moderate to severe scalp psoriasis – one of the difficult-to-treat forms of the disease, which affects approximately half of all psoriasis patients.1-3 The label update is effective in the US immediately, and is based on the proven efficacy and consistent safety profile of Cosentyx from a dedicated Phase III scalp psoriasis trial.6
- Source: pharma.us.novartis
- 545
- February 13, 2018
Cosentyx® FDA New Approvals Scalp psoriasis
Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder

Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to SAGE-217 for the treatment of major depressive disorder (MDD). This is the second Breakthrough Therapy designation granted to Sage since 2016.
- Source: finance.yahoo
- 744
- February 12, 2018
biopharmaceutical FDA major depressive disorder New Approvals
Best tech tools to communicate with patients? Time for doctors to ask

Cultivating a strong relationship with patients can translate into higher satisfaction scores but there is a widespread failure to communicate about the most appropriate way to reach consumers.
- Source: healthcareitnews
- 449
- February 12, 2018
healthcare Market Views
Genentech’s Tecentriq Impresses Again in Late-Stage Kidney Cancer Trial

Genentech’s PD-L1 inhibitor Tecentriq continues to show off its versatility. Monday, the Roche subsidiary announced a combination of Tecentriq and Avastin (bevacizumab) was significantly beneficial to patients with advanced or metastatic renal cell carcinoma (mRCC) who have not received prior systemic active or experimental therapy.
- Source: Biospace
- 655
- February 11, 2018
Clinical Trial inhibitor mRCC Tecentriq
Kinsa launches QuickCare, an FDA-cleared wireless connected thermometer

Smart thermometer and connected health company Kinsa has launched a new wireless version of its device, called Kinsa QuickCare, after securing FDA clearance last month.
- Source: MobileHealthNews
- 871
- February 11, 2018
Company Insight digital health FDA mHealth
SIGA Technologies Announces FDA Accepts NDA and Grants Priority Review for Oral TPOXX to Treat Smallpox

SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGA), a health security company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for its oral formulation of TPOXX® (tecovirimat).
- Source: investor.siga
- 599
- February 9, 2018
DNA FDA New Approvals TPOXX
How mHealth is Changing the Face of Indian Healthcare Sector?

The Indian healthcare sector is growing at a fast pace because of increasing investments from government and private players. With nearly 70 percent of country's population living in rural areas, lack of critical medical facilities such as hospitals and clinics are in total disarray. With the rise of mobile technologies, the health apps are growing rapidly in the Indian market. As a result, mHealth (mobile delivery of healthcare) is gaining ground in India.
- Source: Entrepreneur India
- 543
- February 9, 2018
digital health India Market Views mHealth
AMAG Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application (sNDA) for Feraheme® (ferumoxytol injection)

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) has approved its application to broaden the existing label for Feraheme® (ferumoxytol injection) beyond the current chronic kidney disease (CKD) indication to include all eligible adult Iron Deficiency Anemia (IDA) patients who have intolerance to oral iron or have had unsatisfactory response to oral iron.
- Source: Amagpharma
- 683
- February 8, 2018
chronic kidney disease FDA Feraheme New Approvals
Amazon Wants to Disrupt Health Care in America. In China, Tech Giants Already Have

Amazon and two other American titans are trying to shake up health care by experimenting with their own employees’ coverage. By Chinese standards, they’re behind the curve.
- Source: New York Times
- 567
- February 8, 2018
digital health health IT Market Views
Medial EarlySign’s AI scans medical records for diabetes warning signs

A machine learning technology developed to spot dangerous medical conditions before they worsen has shown its value in a trial.
- Source: PharmaPhorum
- 578
- February 7, 2018
AI diabetes NHS Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.